{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:13:47Z","timestamp":1757618027589,"version":"3.44.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40487-025-00347-1","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:19:47Z","timestamp":1747721987000},"page":"631-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Maria","family":"Quind\u00f3s-Varela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Soto de Prado-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purificaci\u00f3n","family":"Est\u00e9vez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pilar","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Borraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3682-3597","authenticated-orcid":false,"given":"Mar\u00eda Jes\u00fas","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"4","key":"347_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","volume":"29","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, Bois AD, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;29(4):728\u201360.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"347_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, Kobel M, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1):60\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"347_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s12094-020-02545-x","volume":"23","author":"A Redondo","year":"2021","unstructured":"Redondo A, Guerra E, Manso L, et al. SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021;23(5):961\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"347_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"347_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jamaoncol.2016.4411","volume":"3","author":"JA Rauh-Hain","year":"2017","unstructured":"Rauh-Hain JA, Melamed A, Wright A, et al. Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the national cancer database. JAMA Oncol. 2017;3(1):76\u201382.","journal-title":"JAMA Oncol"},{"issue":"1","key":"347_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","volume":"143","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143(1):3\u201315.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"347_CR7","volume":"7","author":"SL Coleridge","year":"2021","unstructured":"Coleridge SL, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;7(7): Cd005343.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"347_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12885-018-4498-z","volume":"18","author":"JY Lee","year":"2018","unstructured":"Lee JY, Kim S, Kim YT, et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18(1):601.","journal-title":"BMC Cancer"},{"issue":"19","key":"347_CR9","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.7150\/jca.26300","volume":"9","author":"J Wu","year":"2018","unstructured":"Wu J, Sun H, Yang L, et al. Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983\u20132012. J Cancer. 2018;9(19):3548\u201356.","journal-title":"J Cancer"},{"issue":"8","key":"347_CR10","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata S, Cecere SC, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28(8):viii51\u20136.","journal-title":"Ann Oncol"},{"key":"347_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","volume":"140","author":"L Daniela","year":"2019","unstructured":"Daniela L, Francesco P, Alessia A, et al. Ovarian cancer relapse: from the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28\u201338.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"347_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40487-023-00227-6","volume":"11","author":"D Chase","year":"2023","unstructured":"Chase D, Perhanidis J, Gupta D, Kalilani L, Golembesky A, Gonz\u00e1lez-Mart\u00edn A. Real-world outcomes following first-line treatment in patients with advanced ovarian cancer with multiple risk factors for disease progression who received maintenance therapy or active surveillance. Oncol Ther. 2023;11(2):245\u201361.","journal-title":"Oncol Ther"},{"issue":"6","key":"347_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","volume":"204","author":"R Salani","year":"2011","unstructured":"Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466\u201378.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"347_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.21037\/gs-20-325","volume":"9","author":"S Garzon","year":"2020","unstructured":"Garzon S, Lagan\u00e0 AS, Casarin J, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118\u201329.","journal-title":"Gland Surg"},{"issue":"27","key":"347_CR15","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.19.00194","volume":"37","author":"E Pujade-Lauraine","year":"2019","unstructured":"Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437\u201348.","journal-title":"J Clin Oncol"},{"issue":"4","key":"347_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(4):771\u20135.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"347_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12889-019-6633-4","volume":"19","author":"KM White","year":"2019","unstructured":"White KM, Seale H, Harrison R. Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation. BMC Public Health. 2019;19(1):296.","journal-title":"BMC Public Health"},{"issue":"26","key":"347_CR18","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"17","key":"347_CR19","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039\u201345.","journal-title":"J Clin Oncol"},{"issue":"13","key":"347_CR20","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"347_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41571-020-0335-9","volume":"17","author":"SN Banerjee","year":"2020","unstructured":"Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer\u2014standard of care for all? Nat Rev Clin Oncol. 2020;17(3):136\u20137.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"347_CR22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31(9):1148\u201359.","journal-title":"Ann Oncol"},{"key":"347_CR23","first-page":"1","volume":"40","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Lheureux S, Moore KN. PARP inhibitors for ovarian cancer: current indications, future combinations, and novel assets in development to target DNA damage repair. Am Soc Clin Oncol Educ Book. 2020;40:1\u201316.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"347_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12094-012-0995-8","volume":"15","author":"A Gonz\u00e1lez Mart\u00edn","year":"2013","unstructured":"Gonz\u00e1lez Mart\u00edn A, Redondo A, Jurado M, et al. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol. 2013;15(7):509\u201325.","journal-title":"Clin Transl Oncol"},{"key":"347_CR25","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.2147\/DDDT.S151420","volume":"11","author":"C Audibert","year":"2017","unstructured":"Audibert C, Perlaky A, Stuntz M, Glass D. Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. Drug Design Dev Ther. 2017;11:3471\u20139.","journal-title":"Drug Design Dev Ther."},{"issue":"15_suppl","key":"347_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e17516","volume":"36","author":"C Karki","year":"2018","unstructured":"Karki C, Patel R, Martino S, Wriede V, Shah-Manek B. Treatment pattern differences across the United States and EU5 among patients with ovarian cancer. J Clin Oncol. 2018;36(15_suppl): e17516.","journal-title":"J Clin Oncol"},{"issue":"6","key":"347_CR27","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.3390\/curroncol28060440","volume":"28","author":"M Liontos","year":"2021","unstructured":"Liontos M, Timotheadou E, Papadopoulos EI, et al. Real-world data on treatment management and outcomes of patients with newly diagnosed advanced epithelial ovarian cancer in greece (the EpOCa Study). Curr Oncol. 2021;28(6):5266\u201377.","journal-title":"Curr Oncol"},{"issue":"8","key":"347_CR28","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.3390\/curroncol29080472","volume":"29","author":"SL Liu","year":"2022","unstructured":"Liu SL, Chan WC, Bouchard-Fortier G, Lheureux S, Ferguson SE, Krzyzanowska MK. Patterns of first-line systemic therapy delivery and outcomes in advanced epithelial ovarian cancer in Ontario. Curr Oncol. 2022;29(8):5988\u20136009.","journal-title":"Curr Oncol"},{"key":"347_CR29","doi-asserted-by":"publisher","first-page":"1114435","DOI":"10.3389\/fonc.2023.1114435","volume":"13","author":"S Cheeseman","year":"2023","unstructured":"Cheeseman S, Levick B, Sopwith W, et al. Ovarian real-world international consortium (ORWIC): a multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. Front Oncol. 2023;13:1114435.","journal-title":"Front Oncol"},{"issue":"15","key":"347_CR30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/fon-2020-0083","volume":"16","author":"JP Hall","year":"2020","unstructured":"Hall JP, Chang J, Moon R, et al. Real-world treatment patterns in patients with advanced (stage III-IV) ovarian cancer in the USA and Europe. Future Oncol. 2020;16(15):1013\u201330.","journal-title":"Future Oncol"},{"issue":"26","key":"347_CR31","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"issue":"7","key":"347_CR32","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.21873\/anticanres.16481","volume":"43","author":"T Fukuda","year":"2023","unstructured":"Fukuda T, Noda T, Uchikura E, et al. Real-world efficacy and safety of bevacizumab for advanced or recurrent m\u00fcllerian cancer: a single-institutional experience. Anticancer Res. 2023;43(7):3097\u2013105.","journal-title":"Anticancer Res"},{"issue":"1","key":"347_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13048-021-00816-x","volume":"14","author":"A Redondo","year":"2021","unstructured":"Redondo A, Oaknin A, Rubio MJ, et al. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021;14(1):72.","journal-title":"J Ovarian Res"},{"issue":"29","key":"347_CR34","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699\u2013707.","journal-title":"J Clin Oncol"},{"key":"347_CR35","doi-asserted-by":"crossref","unstructured":"NCCN. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer v3.2014. 2012;pp. 1\u201377.","DOI":"10.1142\/9781783267316_0007"},{"issue":"6","key":"347_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.31083\/j.ejgo4206163","volume":"42","author":"A Redondo","year":"2021","unstructured":"Redondo A, Giron\u00e9s Sarri\u00f3 R, Ruiz N, et al. Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study). Eur J Gynaecol Oncol. 2021;42(6):1116\u201323.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"347_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","volume":"34","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017;34(6):103.","journal-title":"Med Oncol"},{"key":"347_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007930.pub3","author":"K Gaitskell","year":"2023","unstructured":"Gaitskell K, Rogozi\u0144ska E, Platt S, et al. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD007930.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"347_CR39","unstructured":"European Medicines Agency. Summary of product characteristics. Avastin 25 mg\/ml. [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin."},{"key":"347_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ctrv.2018.06.001","volume":"69","author":"P DiSilvestro","year":"2018","unstructured":"DiSilvestro P, Alvarez SA. Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time? Cancer Treat Rev. 2018;69:53\u201365.","journal-title":"Cancer Treat Rev"},{"issue":"11_suppl","key":"347_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/OP.2023.19.11_suppl.544","volume":"19","author":"DM Chase","year":"2023","unstructured":"Chase DM, Iadeluca L, Lim J, et al. First-line maintenance use among patients with advanced ovarian cancer in a community oncology setting: a retrospective observational study in the United States (US). JCO Oncol Pract. 2023;19(11_suppl):544.","journal-title":"JCO Oncol Pract"},{"key":"347_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341723","volume":"2015","author":"A Toss","year":"2015","unstructured":"Toss A, Tomasello C, Razzaboni E, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015: 341723.","journal-title":"Biomed Res Int"},{"issue":"20","key":"347_CR43","doi-asserted-by":"publisher","first-page":"11239","DOI":"10.3390\/ijms252011239","volume":"25","author":"N Tonti","year":"2024","unstructured":"Tonti N, Golia D\u2019Aug\u00e8 T, Cuccu I, et al. The role of tumor biomarkers in tailoring the approach to advanced ovarian cancer. Int J Mol Sci. 2024;25(20):11239.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"347_CR44","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e104","volume":"35","author":"C Perrone","year":"2024","unstructured":"Perrone C, Angioli R, Luvero D, et al. Targeting BRAF pathway in low-grade serous ovarian cancer. J Gynecol Oncol. 2024;35(4): e104.","journal-title":"J Gynecol Oncol"},{"issue":"34","key":"347_CR45","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952\u201364.","journal-title":"J Clin Oncol"},{"issue":"5","key":"347_CR46","doi-asserted-by":"publisher","first-page":"872","DOI":"10.7150\/jca.17664","volume":"9","author":"M Shimokawa","year":"2018","unstructured":"Shimokawa M, Kogawa T, Shimada T, et al. Overall survival and post-progression survival are potent endpoint in phase III trials of second\/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9(5):872\u20139.","journal-title":"J Cancer"},{"issue":"1","key":"347_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2015","unstructured":"Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21(1):211\u201320.","journal-title":"Clin Cancer Res"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00347-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:06:53Z","timestamp":1757171213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00347-1","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Gonz\u00e1lez-Mart\u00edn declares grants or contracts from GSK, Roche, ISCiii, and AECC; consulting fees from Incyte, Pharmaand, Daichii, Alkermes, Amgen, AstraZeneca, Clovis, Genmab, GSK, HederaDX, Immunogen, Kartos, Karyopharm, Illumina, Mersana, MSD, Novartis, Novocure, Oncoinvent, PharmaMar, Roche, SOTIO, SUTRO, Seagen, Takeda, and Tubulis; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Clovis, GSK, Immunogen, Mersana, MSD, Novocure, PharmaMar, Roche, Takeda, Seagen, and Zai Lab; and support for attending meetings and\/or travel from AstraZeneca, Clovis, GSK, Immunogen, Mersana, MSD, Novocure, PharmaMar, Roche, and Takeda. Alejandro Gallego declares grants or contracts from GEICO and SEOM; consulting fees from GSK, MSD, AstraZeneca, and Clovis; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, AstraZeneca, MSD, Clovis, and GSK; payment for expert testimony from GSK, MSD, AstraZeneca, and Clovis; support for attending meetings and\/or travel from Roche, MSD, GSK, AstraZeneca, and PharmaMar; participation on a data safety monitoring board or advisory board from PharmaMar and GSK; and participation in a company sponsored speaker\u2019s bureau from Roche, AstraZeneca, MSD, Clovis, and GSK. Yolanda Garc\u00eda declares consulting fees from Roche, Astrazeneca, GSK, MSD, and Clovis; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Astrazeneca, GSK, MSD, and Clovis; support for attending meetings and\/or travel from Roche, GSK, and MSD; and participation on a data safety monitoring board or advisory board from Roche, GSK, and Astrazeneca. Eva Guerra declares consulting fees from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro, PharmaMar, and Roche; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro, PharmaMar, Roche, and Eisai; payment for expert testimony from AstraZeneca-MSD, GSK-Tesaro, PharmaMar, Roche, Pharma& and Eisai; support for attending meetings and\/or travel from GSK; and participation on a data safety monitoring board or advisory board from AstraZeneca. Purificaci\u00f3n Est\u00e9vez-Garc\u00eda declares grants or contracts from GSK; consulting fees from GSK, MSD, AstraZeneca, Clovis, PharmaMar, and Eisai; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, MSD, AstraZeneca, Clovis, PharmaMar, and Eisai; support for attending meetings and\/or travel from GSK, MSD, AstraZeneca, Clovis, and PharmaMar; and participation on a data safety monitoring board or advisory board from GSK, MSD, AstraZeneca, Clovis, PharmaMar, and Eisai. Maria Pilar Barretina-Ginesta declares consulting fees from Astrazeneca, Clovis, GSK, MSD, PharmaMar, Pharmaand, Eisai, and Roche; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astrazeneca, Clovis, Eisai, GSK, MSD, Pharmamar, and Roche; support for attending meetings and\/or travel from Astrazeneca, GSK, and MSD; and participation on a data safety monitoring board or advisory board from MSD. Pilar Borraz is a Roche Pharma employee. Maria Quind\u00f3s-Varela, Mar\u00eda Jes\u00fas Rubio, and Diego Soto de Prado-Otero declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The present study identified with the code ML40141 was approved by the Ethics Committee of Hospital Universitari Doctor Josep Trueta de Girona during the meeting held on the 17 July 2018. All patients provided informed consent to participate in the study. The study was performed in accordance with the Declaration of Helsinki (1964 and its later amendments).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}